- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04435223
Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen (COVIDOLIP)
June 19, 2020 updated by: Centre Hospitalier Universitaire Dijon
SARS-COV 2 infection might be responsible for sever pneumonia.
Obesity seems to be a risk factor for severe SARS-COV 2 pneumonia.
Lipid metabolism alteration are described with both obesity and sepsis.
The aim of the present study was to describe association between lipid metabolism, obesity, sepsis inflammation and clinical outcome in COVID-19 patient with severe pneumonia compared with severe pneumonia caused by other pathogenes.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
62
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dijon, France, 21000
- Chu Dijon Bourgogne
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
patient with pneumopathy
Description
Inclusion Criteria:
- 2 of the following criteria: Cough/ Dyspnea/ Spitting/ Thoracic pain/ Hyperthermia (>=38 °C) Hypothermia (< 35°C) AND new radiologic pulmonary infiltrate
- At admission or within 48 hours following hospital admission
- With 2 qSOFA criteria: MAP =< 100 mmHg, Respiratory Rate >= 22, Glasgow score < 15 OR on mechanical ventilation OR under vasopressor
- Age > 18
- affiliated to social security
Exclusion Criteria:
- Pregnancy
- immunodepression
- Pathology known to cause severe lymphopenia
- hospitalisation within 3 month before inclusion AND sepsis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
COVID-19 severe pneumonia
|
bioassays carried out on samples already collected and conserved
|
Severe pneumonia due to other pathogene
|
bioassays carried out on samples already collected and conserved
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cholesterol concentration
Time Frame: Within 48 hours following hospital admission
|
Within 48 hours following hospital admission
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LDL cholesterol / HDL cholesterol/ Lipoprotein size and composition/ Non esterified Fatty acid/ Triglyceridemia/ CETP and PLTP activity/ apolipoprotein canceration/ lipid peroxidation/ Pro and anti inflammatory profile.
Time Frame: Within 48 hours following hospital admission
|
Ventilator free days (28 days)
|
Within 48 hours following hospital admission
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 7, 2020
Primary Completion (ACTUAL)
May 7, 2020
Study Completion (ACTUAL)
May 7, 2020
Study Registration Dates
First Submitted
June 16, 2020
First Submitted That Met QC Criteria
June 16, 2020
First Posted (ACTUAL)
June 17, 2020
Study Record Updates
Last Update Posted (ACTUAL)
June 23, 2020
Last Update Submitted That Met QC Criteria
June 19, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NGUYEN AOIc 2020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19 Severe Pneumonia
-
Ministry of Health, KuwaitUnknownPneumonia, Viral | Moderate COVID-19 Pneumonia, Severe COVID-19 PneumoniaKuwait
-
Novartis PharmaceuticalsNovartis is the Marketing Authorization Holder for Jakavi outside the US.No longer availableSevere/Very Severe COVID-19 Illness
-
University of GiessenCompletedCOVID-19 Pneumonia | Severe Acute Respiratory Syndrome (SARS) PneumoniaGermany
-
Assistance Publique - Hôpitaux de ParisCompleted
-
InflaRx GmbHCompletedSevere COVID-19 PneumoniaBelgium, Brazil, France, Germany, Mexico, Netherlands, Peru, Russian Federation, South Africa
-
Hospital Italiano de Buenos AiresRecruitingTocilizumab | Severe COVID 19 PneumoniaArgentina
-
Hopital of MelunCompletedCOVID-19 Pneumonia | ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2France
-
Grand Medical Pty Ltd.Trium Clinical ConsultingCompleted
-
Emory UniversityNational Cancer Institute (NCI)TerminatedPneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) PneumoniaUnited States
-
George Papanicolaou HospitalGeneral Hospital Of Thessaloniki IppokratioRecruiting
Clinical Trials on biological assays in particular on the lipid metabolism
-
KRKAUniversity Medical Centre Ljubljana; University of Ljubljana School of Medicine... and other collaboratorsCompletedPeripheral Arterial DiseaseSlovenia
-
Centre Hospitalier de CayenneEuropean Regional Development FundRecruitingChildren | Dengue Fever | AdultsFrance
-
Madigan Army Medical CenterUnknownLow Back Pain | Myofascial Pain Syndrome Lower BackUnited States
-
Memorial Sloan Kettering Cancer CenterGlaxoSmithKline; University of WashingtonCompletedProstate Cancer | Castration-resistant, MetastaticUnited States